Related Experiment Video
Updated: Jul 26, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Serologic testing of randomly selected children after hepatitis B vaccination: a cross-sectional population-based
Masataro Norizuki1,2, Tomomi Kitamura3, Kenichi Komada3
1Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. m-norizuki@it.ncgm.go.jp.
Insights
Hepatitis B vaccination in Lao PDR shows extremely low anti-HBs positivity in children, indicating potential issues with vaccine effectiveness. Post-vaccination testing using dried blood spots is crucial for evaluating population immunity.
Area of Science:
- Immunology
- Public Health
- Vaccinology
Background:
- National hepatitis B virus (HBV) vaccination program initiated in Lao PDR in 2002.
- Concerns regarding vaccine inactivation due to cold-chain transport issues in developing countries.
- Need to assess current population immunity against HBV in Lao PDR.
Purpose of the Study:
- Evaluate the effectiveness of the HBV immunization program in Lao PDR.
- Determine the level of population immunity against HBV in children and mothers.
- Assess the utility of dried blood spot (DBS) testing for serologic evaluation.
Main Methods:
- Cross-sectional serologic study in central Lao PDR.
- Probability-proportional-to-size sampling of children (5-9 years) and mothers (15-45 years).
- Analysis of anti-hepatitis B surface (HBs) titers using dried blood spots (DBS) and correlation with serum levels.
Main Results:
- Strong correlation (r=0.999) between anti-HBs titers in DBS and serum.
- 10 mIU/mL serum anti-HBs equivalent to 3.45 mIU/mL DBS anti-HBs.
- Extremely low anti-HBs positivity (0.7%) among children with documented vaccination (≥3 doses).
Conclusions:
- Vaccination program in Lao PDR shows very low seropositivity for anti-HBs.
- Post-vaccination serologic testing is essential for assessing population immunity against HBV.
- DBS testing offers a cost-effective method for evaluating HBV vaccination program effectiveness.
Background:
Population immunity against hepatitis B virus (HBV) in Lao People's Demographic Republic (PDR) has not been examined since the national HBV vaccination program was started in 2002. Vaccine has been observed to be frozen at times during cold-chain transport in vaccination programs in Lao PDR and other developing countries, which will inactivate the vaccine. Therefore, this study used post-vaccination serologic testing to evaluate the effects of HBV immunization in Lao PDR.
Methods:
A cross-sectional serologic study was conducted among children (age range, 5-9 years) and mothers (15-45 years) who were randomly selected using probability-proportional-to-size sampling from central Lao PDR. Blood samples were collected as dried blood spots (DBS) and analyzed using chemiluminescent microparticle immunoassay to detect anti-hepatitis B surface (HBs) titers. We also evaluated the correlation between anti-HBs levels measured in DBS and serum among healthy healthcare workers in Vientiane.
Results:
Anti-HBs titers from DBS were strongly correlated with serum levels (correlation coefficient = 0.999) in all 12 healthcare workers evaluated. A linear regression model showed that 10 mIU/mL of serum anti-HBs was equivalent to 3.45 mIU/mL (95% CI: 3.06-3.85) of DBS. Among 911 mother-child pairs tested, 171 children had documentation of vaccination. Of the 147 children who had received ≥3 doses of the hepatitis B vaccine, 1 (0.7%) was positive for anti-HBs. The remaining 24 children received the hepatitis B vaccine only twice, once or no dose.
Conclusions:
The results showed extremely low positivity for anti-HBs among vaccinated children in central Lao PDR. Therefore, post-vaccination serologic testing is important to evaluate population immunity against HBV infection. DBS testing is a potential low-cost tool to evaluating the effectiveness of HBV vaccination programs.
Related Concept Videos
Cross-reactivity
Hepatitis
Viral Hepatitis I: Introduction

